JLE

Hépato-Gastro & Oncologie Digestive

MENU

Prise en charge thérapeutique des cancers colorectaux métastatiques au-delà de la deuxième ligne Volume 26, numéro 3, Mars 2019

  • [1] Cremolini C., Loupakis F., Antoniotti C. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer : updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol. 2015;16:1306-1315.
  • [2] Venook A.P., Niedzwiecki D., Lenz H.J. Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer : a randomized clinical trial. JAMA. 2017;317:2392-2401.
  • [3] Stintzing S., Modest D.P., Rossius L. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3) : a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial. Lancet Oncol. 2016;17:1426-1434.
  • [4] Kopetz S., Chang G.J., Overman M.J. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol. 2009;27:3677-3683.
  • [5] Tampellini M., Di Maio M., Baratelli C. Treatment of patients with metastatic colorectal cancer in a real-world scenario : probability of receiving second and further lines of therapy and description of clinical benefit. Clin Colorectal Cancer. 2017;16:372-376.
  • [6] Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT) : an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013 ; 381 : 303-12.
  • [7] Mayer RJ, Van Cutsem E, Falcone A, et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med 2015 ; 372 : 1909-19.
  • [8] Li J, Qin S, Xu R, et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2015 ; 16 : 619-29.
  • [9] Xu J, Kim TW, Shen L, et al. Results of a randomized, double-blind, placebo-controlled, phase III trial of trifluridine/tipiracil (TAS-102) monotherapy in Asian patients with previously treated metastatic colorectal cancer : the TERRA study. J Clin Oncol 2018 ; 36 : 350-8.
  • [10] Yoshino T., Kojima T., Bando H. Effect of food on the pharmacokinetics of TAS-102 and its efficacy and safety in patients with advanced solid tumors. Cancer Sci. 2016;107:659-665.
  • [11] Doi T., Ohtsu A., Yoshino T. Phase I study of TAS-102 treatment in Japanese patients with advanced solid tumours. Br J Cancer. 2012;107:429-434.
  • [12] Zopf D., Fichtner I., Bhargava A. Pharmacologic activity and pharmacokinetics of metabolites of regorafenib in preclinical models. Cancer Med. 2016;5:3176-3185.
  • [13] Bruix J., Qin S., Merle P. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389:56-66.
  • [14] Demetri G.D., Reichardt P., Kang Y.K. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib : an international, multicentre, prospective, randomised, placebo-controlled phase 3 trial (GRID). Lancet. 2013;381:295-302.
  • [15] Mross K., Frost A., Steinbild S. A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors. Clin Cancer Res. 2012;18:2658-2667.
  • [16] Strumberg D., Scheulen M.E., Schultheis B. Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study. Br J Cancer. 2012;106:1722-1727.
  • [17] Gerisch M., Hafner F.T., Lang D. Mass balance, metabolic disposition, and pharmacokinetics of a single oral dose of regorafenib in healthy human subjects. Cancer Chemother Pharmacol. 2018;81:195-206.
  • [18] Bekaii-Saab TS, Ou FS, Anderson DM, et al. Regorafenib dose optimization study (ReDOS): Randomized phase II trial to evaluate dosing strategies for regorafenib in refractory metastatic colorectal cancer (mCRC) : An ACCRU Network study. J Clin Oncol 2018 ; 36 (4 suppl) : 611-611.
  • [19] Ren Z., Zhu K., Kang H. Randomized controlled trial of the prophylactic effect of urea-based cream on sorafenib-associated hand-foot skin reactions in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2015;33:894-900.
  • [20] http://www.afsos.org/wp-content/uploads/2016/09/Toxicites_des_therapies_ciblees.pdf.
  • [21] Grothey A. Regorafenib in metastatic colorectal cancer: optimal dosing and patient selection recommendations. Clin Adv Hematol Oncol 2015 ; 13 : 514-7.
  • [22] Smith T.J., Bohlke K., Lyman G.H. Recommendations for the Use of WBC Growth Factors : American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2015;33:3199-3212.
  • [23] Klastersky J., de Naurois J., Rolston K. Management of febrile neutropaenia : ESMO Clinical Practice Guidelines. Ann Oncol. 2016;27:v111-v118. suppl5
  • [24] Van Cutsem E., Mayer R.J., Laurent S. The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer. Eur J Cancer. 2018;90:63-72.
  • [25] Moriwaki T, Fukuoka S, Taniguchi H, et al. Propensity score analysis of regorafenib versus trifluridine/tipiracil in patients with metastatic colorectal cancer refractory to standard chemotherapy (REGOTAS): a Japanese Society for Cancer of the Colon and Rectum multicenter observational study. Oncologist 2018 ; 23:7-15.
  • [26] Ducreux M, Öhler L, Scheithauer W, et al. Impact of tumor location on outcomes in patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG): an interim analysis from the prospective, observational CORRELATE study. J Clin Oncol 2017 ; 35(suppl) : abstract 3567.
  • [27] Grothey A., Huang L., Wagner A., Van Cutsem E. Hand-foot skin reaction (HFSR) and outcomes in the phase 3 CORRECT trial of regorafenib for metastatic colorectal cancer (mCRC). J Clin Oncol. 2017;35:3551-13551. 15 suppl
  • [28] Ricotta R., Verrioli A., Ghezzi S. Radiological imaging markers predicting clinical outcome in patients with metastatic colorectal carcinoma treated with regorafenib: post hoc analysis of the CORRECT phase III trial (RadioCORRECT study). ESMO Open. 2017;1:e000111.
  • [29] Shitara K, Yamanaka T, Denda T, et al. REVERCE: Randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for metastatic colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, and irinotecan. J Clin Oncol 2018 ; 36 (Suppl. 4S) : 557-557.
  • [30] Ohtsu A., Yoshino T., Falcone A. Onset of neutropenia as an indicator of treatment response in the phase 3 RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo in patients with metastatic colorectal cancer. J Clin Oncol. 2017;35:775-1775. 4 suppl